Compare · GLP-1 agonist
Semaglutide vs Survodutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Semaglutide | Survodutide | |
|---|---|---|
| Evidence | Strong human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. | An investigational GLP-1/glucagon dual agonist with solid placebo-controlled Phase 2 trials and one positive Phase 3 topline, but no approval and no peer-reviewed Phase 3 data. |
| Full profile → | Full profile → |
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most compounds we profile, the human evidence here is large, long, and consistent — so the honest job is to describe where it holds up and where it does not.
Survodutide
Survodutide (development code BI 456906) is an investigational injectable drug being studied for obesity, fatty-liver disease, and type 2 diabetes. It has a stronger human evidence base than most peptides sold online, including several well-run placebo-controlled trials and one positive Phase 3…